Research on Breast Cancer Surgery and Implant Options
Women diagnosed with breast cancer who undergo reconstructive surgery after a mastectomy experience lower complication rates when using polyurethane-coated implants, according to recent findings.
In the UK, around 55,000 women are diagnosed with breast cancer annually, and about 30% of those opt for mastectomy, many of whom later receive radiotherapy.
Reconstructive surgery is a common choice, but painful scar tissue, particularly after radiotherapy, can complicate recovery.
There’s been a recognized link between radiotherapy post-mastectomy and an increased likelihood of complications and additional surgeries. However, prior to this study, real-world insights into how different implant types could affect scarring were limited.
A new study highlights that polyurethane-coated implants help in reducing scars and the need for further procedures. These implants are primarily silicone, but feature a soft outer layer of polyurethane.
Researchers across Europe examined around 1,500 women treated for breast cancer between 2016 and 2024. All had mastectomies followed by reconstructive surgery with implants, along with subsequent radiotherapy. A third were given polyurethane-coated implants, while just under 1,000 used standard ones.
Health outcomes were monitored over a two-and-a-half to three-year period. Early results, shared during the European Breast Cancer Conference in Barcelona, indicated that those with polyurethane-coated implants had a notably lower incidence of hardened scar tissue—referred to as capsular contracture.
Specifically, 32.8% of women with polyurethane-coated implants developed capsular contracture, in contrast to nearly half (47.5%) of those who had standard implants. They also faced fewer instances requiring secondary surgery to address scar tissue or combat significant infections.
Dr. Kerstin Wimmer from the Medical University of Vienna noted the study’s findings suggest that polyurethane-coated implants lead to considerably fewer complications after radiotherapy compared to their standard counterparts.
This indicates that the choice of implant can significantly influence complication risks post-radiotherapy, providing key insights for reconstructive planning in patients expected to undergo radiotherapy.
Prof. Isabel Rubio, head of breast surgical oncology at the Clínica Universidad de Navarra, emphasized that these findings could enhance patient comfort and overall quality of life.
As breast cancer care becomes more personalized, this evidence could assist in deciding on implant selections and treatment strategies, with the aim of effectively treating the cancer while also minimizing long-term side effects.
Catherine Priestley, a senior clinical nurse specialist at Breast Cancer Now, highlighted the importance of assessing how different implants interact with radiotherapy regarding complication risks. This information empowers women to make informed choices, ultimately leading to better post-treatment experiences.
She acknowledged the emotional and physical challenges women face when needing additional procedures while adapting to changes following breast cancer treatment.
Meanwhile, Sarah Downey, president of the Association of Breast Surgery, pointed out that breast implants remain an essential option for many reconstruction patients, which can help restore confidence and enhance quality of life. She expressed eagerness for further research in this area.
